ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Nichi-Iko Pharmaceutical Co., Ltd.

Business Summary

Nichi-Iko Pharmaceutical Co., Ltd. engages in the manufacturing, sales, distribution, export, import and related activities for various types of pharmaceutical products. The company provides its products to medical institutions such as hospitals, medical clinics and dispensing pharmacies. Its medical products are divided into ethical pharmaceutical products which are formulated according to a prescription issued by a doctor in a hospitals or clinics, as well as general pharmaceutical products which can be purchased at pharmacies and drugstores without a prescription needed. It also provides treatments for circulatory, digestive, respiratory, central and peripheral nervous systems and others. The company was founded on July 15, 1965 and is headquartered in Toyama, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue190,076M1,748.21M
Gross Profit37,320M343.24M
Operating income7,572M69.64M
Income before tax7,396M68.02M
Net income5,133M47.21M
EBITDA19,443M178.82M
Diluted EPS80.120.73
Dividends Per Share300.27
Total Assets336,819M3,119.99M
Total liabilities219,644M2,034.58M
Total equity115,827M1,072.91M
Operating cash flow18,450M169.69M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 143,513M 149,263M 164,717M 166,592M 190,076M
Gross Profit 53,313M 37,611M 40,803M 33,158M 37,320M
Operating income 12,910M 10,026M 13,200M 7,221M 7,572M
Income before tax 15,359M 5,963M 9,067M 8,903M 7,396M
Net income 11,031M 4,796M 8,069M 6,864M 5,133M
EBITDA 24,200M 17,091M 22,179M 16,987M 19,443M
Diluted EPS 184.01 84.08 142.92 114.03 80.12
Dividends Per Share 30 30 30 30 30
Total Assets 161,128M 268,900M 278,364M 306,838M 336,819M
Total liabilities 78,531M 185,725M 190,819M 190,511M 219,644M
Total equity 82,597M 83,171M 87,542M 116,323M 115,827M
Operating cash flow 7,097M -4,076M 18,925M 23,811M 18,450M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 1,195.10M 1,378.39M 1,486.18M 1,502.25M 1,748.21M
Gross Profit 443.96M 347.32M 368.15M 299.00M 343.24M
Operating income 107.50M 92.58M 119.09M 65.11M 69.64M
Income before tax 127.90M 55.06M 81.80M 80.28M 68.02M
Net income 91.86M 44.28M 72.80M 61.89M 47.21M
EBITDA 201.52M 157.82M 200.11M 153.18M 178.82M
Diluted EPS 1.53 0.77 1.28 1.02 0.73
Dividends Per Share 0.24 0.27 0.27 0.27 0.27
Total Assets 1,433.58M 2,413.17M 2,617.43M 2,772.17M 3,119.99M
Total liabilities 698.70M 1,666.74M 1,794.25M 1,721.19M 2,034.58M
Total equity 734.88M 746.39M 823.14M 1,050.93M 1,072.91M
Operating cash flow 59.10M -37.64M 170.75M 214.71M 169.69M

Valuation Measures

Mar 2020
PER17.74
ROA1.59%
ROE4.42%
Operating margin3.98%
Profit margin2.70%

Key executives

  • President & Representative Director: Yuichi Tamura
  • Finance Manager: Naoyuki Okada
  • Head-Compliance Management & Guidance: Yasutomo Sai
  • Director, VP, Head-CSR, ESG & Business Creation: Kenji Akane
  • Executive Officer & Personnel Manager: Keiichi Arakawa

Shareholders

  • TAMURA YUICHI /NICHI IKO PHARMACEUTICAL/ (12.9%)
  • Hokuhoku Financial Group, Inc. (4.3%)
  • Asset Management One Co., Ltd. (3.9%)
  • Nomura Asset Management Co., Ltd. (2.5%)
  • The Vanguard Group, Inc. (1.8%)
  • Sumitomo Mitsui DS Asset Management Co., Ltd. (1.8%)
  • Dimensional Fund Advisors LP (1.5%)
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan (1.5%)
  • Nipro Corp. (1.4%)
  • Nichi-Iko Pharmaceutical Co., Ltd. (1.4%)

Contact Details

Related Companies

  • Nichi-Iko Pharma Tech Co., Ltd.
  • Elmed Co., Ltd.
  • Nichi Iko Pharmaceutical Trust
  • SterRx LLC
  • Nichi-Iko Pharmaceutical Employee Incentive Plan
  • Nichiiko Pharma KK
  • Nichiiko Osaka KK
  • Yakuhan Pharmaceutical Co., Ltd.
  • Sagent Pharmaceuticals, Inc.
  • Kobayashi Pharmaceutical Industries Co. Ltd.
  • Maruko Pharmaceutical Co. Ltd. /Sale & Marketing Ops./
  • Oriental Pharmaceutical Co., Ltd.
  • Teikoku Medix Co., Ltd.
  • Japan Galen, Inc.
  • Maruko Pharmaceutical Co. Ltd.
  • Nichiiko Pharmaceutical Employee Stock Pwnership Plan

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • Cumberland Pharmaceuticals Inc.
  • Five Prime Therapeutics, Inc.
  • Amphastar Pharmaceuticals Inc
  • Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Class A
Last Updated on 5 Mar, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more